Physician profile
Colt Williams
NPI 1740712108
$6,278.09
in general payments reported to CMS, 2019-2025
40 companies · $3,657 in 2025
The $3,657 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $369 · 2024: $2,252 · 2025: $3,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459 · Long Term Medical Supply Or Device Loan: $1,863 · Consulting Fee: $705 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,458.57 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Consulting Fee | $705.00 |
| Education | $251.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,001.96 | 2024-2025 | |
| Daiichi Sankyo INC. | $1,133.59 | 2023-2025 | Datroway, Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $362.29 | 2023-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $271.88 | 2023-2025 | |
| Abbvie INC. | $248.90 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $218.93 | 2025 | Lynparza, Imfinzi, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $207.78 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Janssen Biotech, INC. | $190.45 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $150.25 | 2025 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $136.55 | 2023-2025 | Libtayo, Lynozyfic |
| Merck Sharp & Dohme LLC | $104.57 | 2024-2025 | Keytruda, Welireg |
| Springworks Therapeutics, INC. | $104.12 | 2024-2025 | Ogsiveo |
| Incyte Corporation | $98.79 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $74.53 | 2024-2025 | Tecentriq, Itovebi, Rozlytrek |
| Ipsen Biopharmaceuticals, INC | $72.90 | 2024-2025 | Onivyde |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.77 | 2024-2025 | |
| Glaxosmithkline, LLC. | $55.45 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Pharmaessentia USA Corporation | $55.21 | 2025 | Besremi |
| Adc Therapeutics America, INC. | $52.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.80 | 2023-2025 | Gilotrif |
| Kyowa Kirin, INC. | $50.81 | 2024-2025 | Poteligeo |
| Mirati Therapeutics, INC. | $49.99 | 2024 | Krazati |
| Servier Pharmaceuticals LLC | $47.14 | 2023-2024 | |
| Array Biopharma INC | $46.52 | 2025 | Braftovi, Tukysa, Mektovi |
| Puma Biotechnology, INC. | $44.43 | 2024-2025 | |
| Caris Mpi, INC. | $43.94 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $39.74 | 2025 | |
| Karyopharm Therapeutics INC. | $34.43 | 2024 | Xpovio |
| Emd Serono, INC. | $34.38 | 2025 | |
| Aveo Pharmaceuticals, INC. | $27.47 | 2025 | |
| Coherus Oncology, INC. | $26.13 | 2024 | |
| Sobi, INC | $25.91 | 2024 | |
| Kite Pharma, INC. | $23.08 | 2025 | Yescarta |
| Tempus Ai, INC | $22.94 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $21.11 | 2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $20.55 | 2025 | Ultomiris |
| Seagen INC. | $19.58 | 2023 | Padcev |
| Lilly USA, LLC | $16.16 | 2025 | Verzenio, Jaypirca |
| Stemline Therapeutics INC. | $14.51 | 2025 | Orserdu |
| Menarini Silicon Biosystems, INC. | $13.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colt Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.